Volume 13, Issue 3 (Aug 2025)
Res Mol Med (RMM) 2025, 13(3): 189-202 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghanei Z, Sefid F. A Novel Chimeric Vaccine Targeting Leukemia Inhibitory Factor and Leukemia Inhibitory Factor Receptor: A Computational Approach to Cancer Immunotherapy. Res Mol Med (RMM) 2025; 13 (3) :189-202
URL: http://rmm.mazums.ac.ir/article-1-621-en.html
URL: http://rmm.mazums.ac.ir/article-1-621-en.html
1- Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran. , Z.Ghanei@alzahra.ac.ir
2- Department of Biology Sciences, School of Materials Engineering and Interdisciplinary Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
2- Department of Biology Sciences, School of Materials Engineering and Interdisciplinary Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract: (238 Views)
Background: Leukemia inhibitory factor (LIF) and LIF receptor (LIFR) are critical mediators of cellular processes, including immune regulation, stem cell maintenance, and tumor progression. In Oncology, aberrant LIF/LIFR signaling promotes tumor survival and immune evasion. This study presents the computational design of a novel chimeric vaccine targeting immunogenic epitopes derived from human LIF and LIFR.
Materials and Methods: We employed comprehensive in silico methods to investigate the biochemical characteristics, immunogenic epitopes, and potential functional domains of LIF and LIFR. After identifying suitable regions and designing a chimeric vaccine, physicochemical properties and 3D structure were predicted using various bioinformatics tools, both individually and in combination.
Results: The results showed highly antigenic B-cell and T-cell epitopes within LIF (amino acids 70-100) and LIFR (amino acids 700-780), as indicated by a VaxiJen score of 0.9737. A multi-epitope construct was engineered by fusing selected epitopes with flexible GGGGS linkers to enhance immunogenicity and structural stability.
Conclusion: A computationally designed chimeric vaccine targeting LIF and LIFR is a promising cancer immunotherapy strategy. Also, success requires rigorous in vivo validation and optimization, highlighting computational biology’s role in cancer treatment innovation and targeting key pathways.
Materials and Methods: We employed comprehensive in silico methods to investigate the biochemical characteristics, immunogenic epitopes, and potential functional domains of LIF and LIFR. After identifying suitable regions and designing a chimeric vaccine, physicochemical properties and 3D structure were predicted using various bioinformatics tools, both individually and in combination.
Results: The results showed highly antigenic B-cell and T-cell epitopes within LIF (amino acids 70-100) and LIFR (amino acids 700-780), as indicated by a VaxiJen score of 0.9737. A multi-epitope construct was engineered by fusing selected epitopes with flexible GGGGS linkers to enhance immunogenicity and structural stability.
Conclusion: A computationally designed chimeric vaccine targeting LIF and LIFR is a promising cancer immunotherapy strategy. Also, success requires rigorous in vivo validation and optimization, highlighting computational biology’s role in cancer treatment innovation and targeting key pathways.
Keywords: Bioinformatics, Cancer immunotherapy, Chimeric vaccine, Leukemia inhibitory factor (LIF)/LIF receptor®
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
